Abstract |
The fusion protein L19mTNF (mouse TNF and human antibody fragment L19 directed to fibronectin extra domain B) selectively targets the tumor vasculature, and in combination with melphalan induces a long-lasting T-cell therapeutic response and immune memory in murine models. Increasing evidence suggests that natural killer (NK) cells act to promote effective T-cell-based antitumor responses. We have analyzed the role of NK cells and dendritic cells (DCs) on two different murine tumor models: WEHI-164 fibrosarcoma and C51 colon carcinoma, in which the combined treatment induces high and low rejection rates, respectively. In vivo NK-cell depletion strongly reduced the rejection of WEHI-164 fibrosarcoma and correlated with a decrease in mature DCs, CD4+ , and CD8+ T cells in the tumor-draining LNs and mature DCs and CD4+ T cells in the tumor 40 h after initiation of the therapy. NK-cell depletion also resulted in the impairment of the stimulatory capability of DCs derived from tumor-draining LNs of WEHI-164-treated mice. Moreover, a significant reduction of M2-type infiltrating macrophages was detected in both tumors undergoing therapy. These results suggest that the efficacy of L19mTNF/ melphalan therapy is strongly related to the early activation of NK cells and DCs, which are necessary for an effective T-cell response.
|
Authors | Enrica Balza, Silvia Zanellato, Alessandro Poggi, Daniele Reverberi, Anna Rubartelli, Lorenzo Mortara |
Journal | European journal of immunology
(Eur J Immunol)
Vol. 47
Issue 4
Pg. 743-753
(04 2017)
ISSN: 1521-4141 [Electronic] Germany |
PMID | 28198545
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Chemical References |
- Antineoplastic Agents, Alkylating
- L19mTNFalpha protein
- Recombinant Fusion Proteins
- Melphalan
|
Topics |
- Animals
- Antineoplastic Agents, Alkylating
(therapeutic use)
- CD4-Positive T-Lymphocytes
(drug effects, immunology)
- Cell Differentiation
- Cell Line, Tumor
- Colorectal Neoplasms
(drug therapy)
- Dendritic Cells
(drug effects, immunology)
- Disease Models, Animal
- Drug Therapy, Combination
- Fibrosarcoma
(drug therapy)
- Humans
- Killer Cells, Natural
(drug effects, immunology)
- Lymphocyte Activation
- Lymphocyte Depletion
- Melphalan
(therapeutic use)
- Mice
- Mice, Inbred BALB C
- Recombinant Fusion Proteins
(therapeutic use)
- T-Lymphocytes, Cytotoxic
(drug effects, immunology)
- Tumor Burden
(drug effects)
|